Evidence map›Paper›PMID 33081776›Full record

Observational studyBMC health services research2020

Costs and healthcare utilisation of patients with heart failure in Spain.

Carlos Escobar, Luis Varela, Beatriz Palacios, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Roberto Alcázar, Nicolás Manito, Manuel Botana

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Carlos EscobarUniversity Hospital La Paz, Madrid, Spain. escobar_cervantes_carlos@hotmail.com.ORCID http://orcid.org/0000-0001-5584-4735
Luis VarelaAstraZeneca Spain, Barcelona, Spain.
Beatriz PalaciosAstraZeneca Spain, Barcelona, Spain.
Margarita CapelAstraZeneca Spain, Barcelona, Spain.
Antoni SicrasHealth Economics and Outcomes Research, Atrys Health, Barcelona, Spain.
Aram SicrasHealth Economics and Outcomes Research, Atrys Health, Barcelona, Spain.
Antonio HormigoPrimary Care Center Salud Puerta Blanca, Malaga, Spain.
Roberto AlcázarUniversity Hospital Infanta Leonor, Madrid, Spain.
Nicolás ManitoHospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Manuel BotanaHospital Universitario Lucus Augusti, Lugo, Spain.
AstraZeneca (Spain) · ESBellvitge University Hospital · ESHospital Universitario Infanta Leonor · ESHospital Universitario La Paz · ESHospital Universitario Lucus Augusti · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain.

methodsObservational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019.

resultsWe identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015-2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs.

conclusionsDuring the 2015-2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

Indexed as

AgedAged, 80 and overDrug CostsFemaleHealth Care CostsHeart FailureHospitalizationHumansMalePatient Acceptance of Health CareRetrospective StudiesSpainDapagliflozinDAPA-HFHeart failureHeart failure costHospitalizationSacubitril/valsartan

Identifiers

PMID33081776
PMCPMC7576860
OpenAlexW3094067118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.